Last reviewed · How we verify
ROP
ROP is a retinoid X receptor (RXR) agonist that modulates nuclear receptor signaling to regulate gene expression involved in metabolic and inflammatory pathways.
ROP is a retinoid X receptor (RXR) agonist that modulates nuclear receptor signaling to regulate gene expression involved in metabolic and inflammatory pathways. Used for Type 2 diabetes (marketed in some regions), Dyslipidemia.
At a glance
| Generic name | ROP |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | RXR agonist |
| Target | RXR (Retinoid X Receptor) |
| Modality | Small molecule |
| Therapeutic area | Metabolic/Oncology |
| Phase | FDA-approved |
Mechanism of action
ROP activates retinoid X receptors, which are nuclear receptors that heterodimerize with other nuclear receptors to control transcription of genes involved in lipid metabolism, glucose homeostasis, and immune regulation. This mechanism allows modulation of metabolic and inflammatory processes relevant to metabolic diseases and certain cancers.
Approved indications
- Type 2 diabetes (marketed in some regions)
- Dyslipidemia
Common side effects
- Headache
- Peripheral edema
- Weight gain
- Elevated triglycerides
Key clinical trials
- Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)
- An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
- A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)
- Retinopathy of Prematurity - Visual Function and Retinal Structure
- Bevacizumab Treatment For Type 1 ROP (PHASE2)
- Study of the Implication of Omega-3 Polyunsaturated Fatty Acids in Retinopathy of Prematurity in New-born Infants (NA)
- Pain and Comfort in the Examination of Retinopathy of Prematurity (NA)
- ROP Check Database Premature Infant Outcomes
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |